Focus: Grifols is a diagnostics and plasma derivatives company headquartered in New York, operating as a publicly traded entity since 1909 with a focus on rare diseases and blood-derived therapies.
Profile data last refreshed 22h ago · AI intelligence enriched 2w ago
No open roles listed right now. Follow Grifols to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Generic commodity product providing stable but declining revenue base.
Help build intelligence for Grifols
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Grifols's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Health Canada imposes new conditions on Grifols after deaths of two people who donated plasma - The Globe and Mail
Health Canada imposes new conditions on Grifols after deaths of two people who donated plasma The Globe and Mail
Inspection of plasma giant Grifols’ head office found ‘deficiencies’: Health Canada - TorontoToday.ca
Inspection of plasma giant Grifols’ head office found ‘deficiencies’: Health Canada TorontoToday.ca
Health Canada reviewing deaths of two people who donated plasma at private centres in Winnipeg - The Globe and Mail
Health Canada reviewing deaths of two people who donated plasma at private centres in Winnipeg The Globe and Mail
No open positions listed yet. Check their careers page directly.
Source: USCIS H-1B Employer Data Hub
Canadian regulatory sanctions (plasma center deaths, Health Canada inspection deficiencies in March–April 2026) present material operational and reputational risk; potential downstream impact on R&D resourcing.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo